E²-RADIatE (EORTC 1811)

• Research type

  Research Study

• Full title

  E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

• IRAS ID

  287688

• Contact name

  Corinne Faivre-Finn

• Contact email

  corinne.finn@nhs.net

• Sponsor organisation

  EORTC - European Organisation for Research and Treatment of Cancer

• Duration of Study in the UK

  5 years, 0 months, 1 days

• Research summary

  This study will collect real-world data from cancer patients treated with standard of care radiotherapy, to support radiotherapy research and provide evidence of the role of radiation oncology.

  Radiotherapy plays a major role in the treatment of patients with cancer. Over the last decade radiotherapy treatments have evolved dramatically and quickly, typically with limited formal evaluation of clinical impact.
  Conventional clinical trials are challenging for the evaluation technical changes, and often under-represent patient groups (e.g. those with co-morbidities and elderly patients).

  The study will link clinical information with diagnostic imaging data, radiation imaging and treatment data, as well as with health economic data and health-related quality of life.

  Specific projects, called cohorts, will be designed for patients to take part in.
  The information collected in each cohort may be used to look at ways of improving radiotherapy such as:
  - identifying patterns of care and factors that influence care and patient outcomes
  - analysing the disease course and treatment for cancer patients treated with radiotherapy
  - developing standards of care for new radiation treatments, techniques and technologies
  - generating new evidence regarding new treatments, techniques and technologies
  - improving the overall quality of radiotherapy delivered in Europe
  - analysing participant health-related quality of life
  - analysing the health economic impact of radiotherapy

  The study will take place in the UK and in several other countries. It is open to cancer patients aged 12 and over who are receiving radiotherapy. There is no upper limit to the number of people who can participate. The study will be open as long as it is scientifically and ethically relevant and practically possible.

  This is a joint initiative developed by the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO).

• REC name

  Yorkshire & The Humber - South Yorkshire Research Ethics Committee

• REC reference

  21/YH/0039

• Date of REC Opinion

  9 Feb 2021

• REC opinion

  Favourable Opinion